Bamlanivimab plus etesevimab in mild or moderate Covid-19
…, PJ Ebert, RE Higgs, NL Kallewaard… - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, …
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, …
[PDF][PDF] Structure and function analysis of an antibody recognizing all influenza A subtypes
NL Kallewaard, D Corti, PJ Collins, U Neu… - Cell, 2016 - cell.com
Influenza virus remains a threat because of its ability to evade vaccine-induced immune
responses due to antigenic drift. Here, we describe the isolation, evolution, and structure of a …
responses due to antigenic drift. Here, we describe the isolation, evolution, and structure of a …
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial
…, NL Kallewaard, J Sabo, DR Patel, P Klekotka, L Shen… - Jama, 2021 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide.
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …
Potently neutralizing and protective human antibodies against SARS-CoV-2
…, JJ Steinhardt, K Ren, YM Loo, NL Kallewaard… - Nature, 2020 - nature.com
The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health …
[PDF][PDF] LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
…, J Chen, BA Heinz, RE Higgs, NL Kallewaard… - Cell reports, 2022 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (…
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (…
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
…, AS Herbert, JM Dye, H Bright, NL Kallewaard… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
Rapid development of broadly influenza neutralizing antibodies through redundant mutations
L Pappas, M Foglierini, L Piccoli, NL Kallewaard… - Nature, 2014 - nature.com
The neutralizing antibody response to influenza virus is dominated by antibodies that bind
to the globular head of haemagglutinin, which undergoes a continuous antigenic drift, …
to the globular head of haemagglutinin, which undergoes a continuous antigenic drift, …
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Q Zhu, JS McLellan, NL Kallewaard… - Science translational …, 2017 - science.org
Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health
priority. However, no vaccine is currently available to protect this vulnerable population. …
priority. However, no vaccine is currently available to protect this vulnerable population. …
[HTML][HTML] Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus
NL Kallewaard, AL Bowen, JE Crowe Jr - Virology, 2005 - Elsevier
Many paramyxoviruses appear to require cytoskeletal elements for particular steps in the
virus life cycle. Measles virus and Sendai virus exhibit a requirement for microtubules in …
virus life cycle. Measles virus and Sendai virus exhibit a requirement for microtubules in …
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID …
…, J Potts, L Baracco, L Macpherson, NL Kallewaard… - MedRxiv, 2022 - medrxiv.org
BACKGROUND Bebtelovimab is a potent, fully human IgG1 monoclonal antibody (mAb)
targeting the S-protein of SARS-CoV-2, with broad neutralizing activity to all currently known …
targeting the S-protein of SARS-CoV-2, with broad neutralizing activity to all currently known …
